CN105254477A - Medicine composition for treatment of vaginitis - Google Patents
Medicine composition for treatment of vaginitis Download PDFInfo
- Publication number
- CN105254477A CN105254477A CN201510776130.9A CN201510776130A CN105254477A CN 105254477 A CN105254477 A CN 105254477A CN 201510776130 A CN201510776130 A CN 201510776130A CN 105254477 A CN105254477 A CN 105254477A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- treatment
- colpitic
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
Abstract
The invention relates to a medicine composition for treatment of vaginitis. The medicine composition includes an effective dose of compound and a pharmaceutically-acceptable carrier. The compound is of the structure as follows (please see the specification for the formula). The compound has an obvious effect on pathogenic bacteria giving rising to vaginitis, and can be developed into a novel clinically-effective medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to one and treat colpitic pharmaceutical composition.
Background technology
Vaginitis is gynaecology's common disease, and it is often because various pathogens causes, and the suppression therefore studied for pathogenic bacterium has great importance for treatment vaginitis.In colpitic patient illness part secretory product, find that in the recent period micrococcus scarlatinae ATCC12344 is also one of pathogenic bacterium wherein.
Summary of the invention
One is the object of the present invention is to provide to treat colpitic pharmaceutical composition.
In order to realize object of the present invention, the invention provides one and treat colpitic compound, this compound has having structure:
The present invention also provides one to treat colpitic pharmaceutical composition, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the colpitic medicine of preparation treatment, and this compound has having structure:
Preferably, described infection is caused by micrococcus scarlatinae ATCC12344.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition micrococcus scarlatinae ATCC12344, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for causing colpitic pathogenic bacteria Be very effective, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition micrococcus scarlatinae ATCC12344
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination bacterial classification micrococcus scarlatinae ATCC12344 purchased from Bei Nuo bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Micrococcus scarlatinae ATCC12344 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 15000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of micrococcus scarlatinae ATCC12344 is 13.78mm, and this shows that target compound has the effect of extremely strong vitro inhibition micrococcus scarlatinae ATCC12344.
Claims (9)
1. treat a colpitic compound, it is characterized in that, this compound has having structure:
2. treat a colpitic pharmaceutical composition, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the colpitic pharmaceutical composition for the treatment of according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the colpitic pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the colpitic pharmaceutical composition for the treatment of according to claim 4, is characterized in that, described thinner is lactose.
6. the colpitic pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the colpitic medicine of preparation treatment, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by micrococcus scarlatinae ATCC12344.
9. the purposes of compound in the medicine of preparation vitro inhibition micrococcus scarlatinae ATCC12344, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776130.9A CN105254477A (en) | 2015-11-13 | 2015-11-13 | Medicine composition for treatment of vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776130.9A CN105254477A (en) | 2015-11-13 | 2015-11-13 | Medicine composition for treatment of vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105254477A true CN105254477A (en) | 2016-01-20 |
Family
ID=55094477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510776130.9A Pending CN105254477A (en) | 2015-11-13 | 2015-11-13 | Medicine composition for treatment of vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105254477A (en) |
-
2015
- 2015-11-13 CN CN201510776130.9A patent/CN105254477A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105395538A (en) | Medicine composition treating acute upper respiratory infection | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105330610A (en) | Medicine composition for treating gingivitis | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160120 |
|
| RJ01 | Rejection of invention patent application after publication |